Ask AI
ProCE Banner Activity

EMERALD-3: Phase III Trial of Tremelimumab + Durvalumab ± Lenvatinib Combined With TACE in Unresectable Embolization-Eligible HCC

Conference Coverage
Slideset

Results from the phase III EMERALD-3 trial showed clinically meaningful and statistically significant survival benefits with tremelimumab plus durvalumab (STRIDE) with or without lenvatinib combined with TACE vs TACE alone in patients with unresectable embolization-eligible HCC.

Released: June 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Incyte Corporation.

Incyte Corporation

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of gastrointestinal cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from gastrointestinal cancer studies at ASCO 2026 and expert guidance to optimize patient selection, sequencing, and monitoring across major gastrointestinal malignancies

  • Utilize prognostic and predictive biomarkers to accurately identify gastrointestinal cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for gastrointestinal cancer to accelerate their effective incorporation into clinical practice